Can cathepsin-D and galectin-3 be new inflammation biomarkers in detection of lysosomal diseases?

Ergün, Pelin; Kağnıcı, Mehtap; Uçar, Sema Kalkan; Çöker, Mahmut; Akçay, Yasemin; Sözmen, Eser Yıldırım

doi:10.1016/j.ymgme.2014.12.079

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gal-3 was the best biomarker for clinical cardiac involvement, and was significantly associated with the whole spectrum of the studied correlations. This biomarker has been proposed as biomarker of fibrosis or remodelling 21 , and it is higher in patients with lysosomal diseases 22 . We therefore propose that Gal-3 may be implicated in the early stages of organ involvement in patients with FD, including cardiac or renal remodelling, as suggested by the strong association with MSSI sub-scores and all the parameters of clinical involvement.…”

Section: Discussionmentioning

confidence: 99%

Galectin-3 and β-trace protein concentrations are higher in clinically unaffected patients with Fabry disease

Hernández-Romero

Sánchez-Quiñones

Vı́lchez

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Current therapies have not shown benefit in organ damage reversal in Fabry disease (FD), but biomarkers could help risk stratification and prognosis. We investigated if several biomarkers of cardiac fibrosis, cardiac wall stress, myocardial injury, renal function and inflammation, are associated with early cardiac affectation in FD patients. We included FD patients from four cardiology outpatient clinics of southeastern Spain. At inclusion, Galectin-3 (Gal-3), N-terminal proB-type natriuretic peptide, high sensitivity troponin T (hsTnT), β-trace protein (BTP) and interleukin-6 concentrations were measured. The relation of biomarkers concentrations with clinical features, cardiac involvement and organ affectation according to the Mainz Severity Score Index (MSSI) was investigated. 44 FD patients (n = 21 affected and n = 23 unaffected) were compared to age and sex-respectively matched healthy controls. Significant differences in biomarkers’ concentration between FD groups were observed. Importantly, Gal-3 and BTP levels were higher in unaffected patients when compared with age and sex-matched healthy controls (both p < 0.05). All the biomarkers correlated with clinical features. When cut-off values for clinical affectation (measured as MSSI ≥ 20) were established, only hsTnT (OR 30.69, 95% CI 2.70–348.42) and male sex (OR 8.17, 95% CI 1.16–57.75) were independently associated with cardiac damage by multivariate regression analysis. Gal-3 and BTP levels are increased in unaffected FD patients compared to healthy controls. This suggests that these biomarkers could be useful for the early detection of cardiac affectation in FD patients. On the other hand, hsTnT and male sex are independent risk factors for established clinical cardiac damage in FD.

show abstract

Section: Discussionmentioning

confidence: 99%